These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 28053692)

  • 1. Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways.
    Mastrocola R; Penna C; Tullio F; Femminò S; Nigro D; Chiazza F; Serpe L; Collotta D; Alloatti G; Cocco M; Bertinaria M; Pagliaro P; Aragno M; Collino M
    Oxid Med Cell Longev; 2016; 2016():5271251. PubMed ID: 28053692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury.
    Sandanger Ø; Ranheim T; Vinge LE; Bliksøen M; Alfsnes K; Finsen AV; Dahl CP; Askevold ET; Florholmen G; Christensen G; Fitzgerald KA; Lien E; Valen G; Espevik T; Aukrust P; Yndestad A
    Cardiovasc Res; 2013 Jul; 99(1):164-74. PubMed ID: 23580606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of autophagy inhibits nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome activation and attenuates myocardial ischemia-reperfusion injury in diabetic rats.
    Zhang D; He Y; Ye X; Cai Y; Xu J; Zhang L; Li M; Liu H; Wang S; Xia Z
    J Diabetes Investig; 2020 Sep; 11(5):1126-1136. PubMed ID: 32064785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway.
    Zhang J; Huang L; Shi X; Yang L; Hua F; Ma J; Zhu W; Liu X; Xuan R; Shen Y; Liu J; Lai X; Yu P
    Aging (Albany NY); 2020 Nov; 12(23):24270-24287. PubMed ID: 33232283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maladaptive Modulations of NLRP3 Inflammasome and Cardioprotective Pathways Are Involved in Diet-Induced Exacerbation of Myocardial Ischemia/Reperfusion Injury in Mice.
    Mastrocola R; Collino M; Penna C; Nigro D; Chiazza F; Fracasso V; Tullio F; Alloatti G; Pagliaro P; Aragno M
    Oxid Med Cell Longev; 2016; 2016():3480637. PubMed ID: 26788246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse.
    Toldo S; Marchetti C; Mauro AG; Chojnacki J; Mezzaroma E; Carbone S; Zhang S; Van Tassell B; Salloum FN; Abbate A
    Int J Cardiol; 2016 Apr; 209():215-20. PubMed ID: 26896627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The protective effect of Luteolin on myocardial ischemia/reperfusion (I/R) injury through TLR4/NF-κB/NLRP3 inflammasome pathway.
    Zhang X; Du Q; Yang Y; Wang J; Dou S; Liu C; Duan J
    Biomed Pharmacother; 2017 Jul; 91():1042-1052. PubMed ID: 28525945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades.
    Penna C; Aragno M; Cento AS; Femminò S; Russo I; Bello FD; Chiazza F; Collotta D; Alves GF; Bertinaria M; Zicola E; Mercurio V; Medana C; Collino M; Pagliaro P
    Oxid Med Cell Longev; 2020; 2020():9219825. PubMed ID: 32832010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naoxintong attenuates Ischaemia/reperfusion Injury through inhibiting NLRP3 inflammasome activation.
    Wang Y; Yan X; Mi S; Li Z; Wang Y; Zhu H; Sun X; Zhao B; Zhao C; Zou Y; Hu K; Ding X; Sun A; Ge J
    J Cell Mol Med; 2017 Jan; 21(1):4-12. PubMed ID: 27785882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse.
    Toldo S; Mauro AG; Cutter Z; Van Tassell BW; Mezzaroma E; Del Buono MG; Prestamburgo A; Potere N; Abbate A
    J Cardiovasc Pharmacol; 2019 Apr; 73(4):215-222. PubMed ID: 30747785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel NLRP3 inhibitor INF195: Low doses provide effective protection against myocardial ischemia/reperfusion injury.
    Gastaldi S; Giordano M; Blua F; Rubeo C; Boscaro V; Femminò S; Comità S; Gianquinto E; Landolfi V; Marini E; Gallicchio M; Spyrakis F; Pagliaro P; Bertinaria M; Penna C
    Vascul Pharmacol; 2024 Sep; 156():107397. PubMed ID: 38897555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NLRP3 Inflammasome in Cardioprotective Signaling.
    Zuurbier CJ
    J Cardiovasc Pharmacol; 2019 Oct; 74(4):271-275. PubMed ID: 31356546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury.
    Liu Y; Lian K; Zhang L; Wang R; Yi F; Gao C; Xin C; Zhu D; Li Y; Yan W; Xiong L; Gao E; Wang H; Tao L
    Basic Res Cardiol; 2014; 109(5):415. PubMed ID: 25015733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-495 Ameliorates Cardiac Microvascular Endothelial Cell Injury and Inflammatory Reaction by Suppressing the NLRP3 Inflammasome Signaling Pathway.
    Zhou T; Xiang DK; Li SN; Yang LH; Gao LF; Feng C
    Cell Physiol Biochem; 2018; 49(2):798-815. PubMed ID: 30165354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Deletion or Pharmacological Inhibition of Soluble Epoxide Hydrolase Ameliorates Cardiac Ischemia/Reperfusion Injury by Attenuating NLRP3 Inflammasome Activation.
    Darwesh AM; Keshavarz-Bahaghighat H; Jamieson KL; Seubert JM
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31319469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-Asarone Alleviates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammatory Response and NLRP3 Inflammasome Mediated Pyroptosis.
    Xiao B; Huang X; Wang Q; Wu Y
    Biol Pharm Bull; 2020 Jul; 43(7):1046-1051. PubMed ID: 32321872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ghrelin protects the heart against ischemia/reperfusion injury via inhibition of TLR4/NLRP3 inflammasome pathway.
    Wang Q; Lin P; Li P; Feng L; Ren Q; Xie X; Xu J
    Life Sci; 2017 Oct; 186():50-58. PubMed ID: 28782532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artemisinin suppresses myocardial ischemia-reperfusion injury via NLRP3 inflammasome mechanism.
    Wang F; Gao Q; Yang J; Wang C; Cao J; Sun J; Fan Z; Fu L
    Mol Cell Biochem; 2020 Nov; 474(1-2):171-180. PubMed ID: 32729005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathelicidin aggravates myocardial ischemia/reperfusion injury via activating TLR4 signaling and P2X
    Wu Y; Zhang Y; Zhang J; Zhai T; Hu J; Luo H; Zhou H; Zhang Q; Zhou Z; Liu F
    J Mol Cell Cardiol; 2020 Feb; 139():75-86. PubMed ID: 31982429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective Nlrp3 inflammasome inhibitor Mcc950 attenuates lung ischemia-reperfusion injury.
    Xu KY; Wu CY; Tong S; Xiong P; Wang SH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):3031-3037. PubMed ID: 30146255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.